Cookies

Like most websites The Medicine Maker uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Discovery & Development Clinical Trials, Drug Delivery

Bringing Alzheimer’s in from the Cold

You’d be forgiven for thinking that the pharma industry has completely abandoned Alzheimer’s disease (AD) research. At the start of 2018, Pfizer made the decision to terminate its neuroscience discovery programs, leading to a significant backlash in the media with dramatic (and negative) headlines lamenting big pharma’s exit from the field. Over the past few years, numerous pharma companies have seen failures of once promising Alzheimer's drugs in their pipelines, and there hasn’t been a new drug approved for AD in over a decade.

Is there truly no hope left? Pfizer’s announcement in January wasn’t all doom and gloom – the company added that it would be creating a venture fund to invest in biotech companies conducting promising neuroscience research. And research in both company pipelines and academia continues. Here, I speak with some of the people refusing to give up on Alzheimer’s.

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

About the Author

Roisin McGuigan

I have an extensive academic background in the life sciences, having studied forensic biology and human medical genetics in my time at Strathclyde and Glasgow Universities. My research, data presentation and bioinformatics skills plus my ‘wet lab’ experience have been a superb grounding for my role as a Deputy Editor at Texere Publishing. The job allows me to utilize my hard-learned academic skills and experience in my current position within an exciting and contemporary publishing company.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register